I
InfaCare Pharmaceutical
Engaged in the development of pharmaceuticals for the neonatal and pediatric patient population
About InfaCare Pharmaceutical
InfaCare Pharmaceutical Corporation was a specialty pharmaceutical company focused on developing and commercializing products for the neonatal and pediatric population. Founded in 2001 by Robert Vukovich, the Pennsylvania-based firm directed its efforts towards addressing unmet medical needs in newborns. The company's operations were centered around its lead drug candidate, stannsoporfin, a first-in-class heme oxygenase inhibitor.
The core of InfaCare's business was the clinical development of stannsoporfin (brand name Stanate) for the treatment of neonatal hyperbilirubinemia, commonly known as infant jaundice. This condition, resulting from high levels of bilirubin, can lead to severe neurological damage if not effectively managed. Stannsoporfin's mechanism of action involves inhibiting the production of bilirubin, offering a preventative pharmacological approach rather than treatments like phototherapy or exchange transfusions, which only address the issue after bilirubin levels have already risen. The product was designed to be administered as a single intramuscular injection to newborns at risk, potentially reducing the need for more invasive procedures.
Throughout its history, InfaCare was a venture-capital-backed entity, raising a total of $78.2 million over 14 funding rounds from investors including Longitude Capital, Healthcare Ventures, and Atlas Venture. A significant milestone was the completion of its Phase IIB clinical trial for stannsoporfin in 2016, after which the company reached an agreement with the U.S. Food and Drug Administration (FDA) to file a New Drug Application (NDA) based on the existing data.
In August 2017, Mallinckrodt plc entered into an agreement to acquire InfaCare, a deal that was finalized in September 2017. The transaction involved an upfront payment of $80 million, with up to $345 million in potential future payments contingent on regulatory and sales milestones. However, the development of stannsoporfin faced a major setback in May 2018 when an FDA advisory committee voted overwhelmingly against its approval, citing insufficient efficacy and safety data. This was followed by the FDA issuing a complete response letter in August 2018, formally rejecting the drug's application.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2005
- Headquarters
- Upper Merion Township, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 45.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Aug 2017 | $425M | — | Mallinckrodt | — |
| LATE VCOther financing | Jul 2015 | $12M | $48M | Undisclosed | — |
Growth signals
Latest recorded traffic for InfaCare Pharmaceutical is 190 monthly website visits. InfaCare Pharmaceutical's team grew 40% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
InfaCare Pharmaceutical in the Upper Merion Township ecosystem
The InfaCare Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Atlas Venture- HVHealthCare Ventures
Longitude Capital
Other known investors1 additional known investor
Mallinckrodt
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about InfaCare Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See InfaCare Pharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








